<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02082236</url>
  </required_header>
  <id_info>
    <org_study_id>SAP101</org_study_id>
    <nct_id>NCT02082236</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects</brief_title>
  <official_title>Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AcelRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AcelRx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the single and multiple-dose pharmacokinetics (PK)
      of sublingual administration of the Sufentanil Sublingual Microtablet (SSM) 30 mcg and
      compare the pharmacokinetics of a single dose of SSM 30 mcg to 2 doses of SSM 15 mcg
      administered 20 minutes apart.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve</measure>
    <time_frame>9 days, not including a 30 day screening window</time_frame>
    <description>Area under the plasma concentration time curve</description>
  </primary_outcome>
  <other_outcome>
    <measure>C max</measure>
    <time_frame>9 days</time_frame>
    <description>Maximum plasma concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>T max</measure>
    <time_frame>9 days</time_frame>
    <description>Time to reach maximum plasma concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Context Sensitive Half-Time (CST½)</measure>
    <time_frame>9 hours</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sufenta® IV (50 mcg/mL) 30 mcg infused over 1 minute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of SSM 30 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 consecutive doses of SSM 15 mcg administered 20 minute apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 consecutive doses of SSM 30 mcg administered 1 hour apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment Arm A: Sufenta®</intervention_name>
    <description>Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B: Sufentanil SSM 30 mcg</intervention_name>
    <description>single-dose SSM 30 mcg</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C: SSM 15 mcg</intervention_name>
    <description>2 consecutive doses of SSM 15 mcg administered 20 minutes apart</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment D: SSM 30 mcg</intervention_name>
    <description>12 consecutive doses of SSM 30 mcg administered 1 hour apart</description>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non-smoking male or female subjects

          2. Aged between 18 and 45 years inclusive

          3. Subjects must have Body Mass Index (BMI) between 18 and 30, inclusively.

        Exclusion Criteria:

          1. Subjects who are taking over-the-counter medication (except for single dose
             multi-vitamin supplements or acetaminophen of less than 2 g/day) within 14 days prior
             to start of sufentanil dosing prescription medications or over the counter (OTC)
             medications

          2. Female subjects who are pregnant

          3. Subjects with chronic obstructive pulmonary disease, sleep apnea, or other significant
             respiratory disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra K. Willsie, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2014</study_first_submitted>
  <study_first_submitted_qc>March 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2014</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasma concentrations</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

